18F-grazy-02

18F-grazy-02 is a fluorine-18 labeled radiopharmaceutical developed by the Peking University Cancer Hospital & Institute. It serves as a positron emission tomography (PET) imaging tracer specifically designed to bind to Granzyme B (GZMB), a key effector molecule released by activated cytotoxic T lymphocytes and natural killer cells during an immune response. By quantifying Granzyme B expression in the tumor microenvironment, 18F-grazy-02 PET/CT imaging allows for the non-invasive monitoring of immune activation in patients undergoing immunotherapy, such as immune checkpoint inhibition or CAR-T cell therapy. This diagnostic tool is being evaluated in clinical trials for its ability to predict early treatment response and differentiate responders from non-responders in patients with lymphoma, non-small cell lung cancer (NSCLC), and melanoma.

Other names

[18F]grazy-0218F-labeled granzyme B tracer